New Protein May Slow, Perhaps Reverse Parkinson's Disease Symptoms
Featured ArticleMain Category: Parkinson's Disease
Also Included In: Neurology / Neuroscience; Clinical Trials / Drug Trials
Article Date: 14 Jul 2007 - 10:00 PDT
| Patient / Public: | ![]() |
4.69 (16 votes) |
| Healthcare Prof: | ![]() |
4.33 (6 votes) |
| Article Opinions: | 1 posts |
Scientists in Finland believe they have found a protein that can prevent the degeneration of cells that produce dopamine. In a patient with Parkinson's, these nerve cells, which produce dopamine, are destroyed.
The scientists believe this chemical may lead the way to treatment which would encourage the damaged cells to recover. Drugs today do not prevent the degeneration of nerve cells.
You can read about this study in the journal Nature.
In this study, scientists injected the protein - CDNF (dopamine neurotrophic factor) - into rats with symptoms of Parkinson's. The rats' symptoms improved; 96% of their nerve cells were protected from degeneration.
Previous studies had focused on another protein, GDNF. As GDNF raised serious safety concerns, they decided to examine CDNF, a related protein (a growth factor). CDNF was found to be better tolerated.
The researchers discovered that CDNF is specific to brain nerve cells. This is not the case with other similar growth factors.
In a further study, the researchers allowed the rats' Parkinson's to progress further. Their aim was to see whether CDNF might help repair damaged nerves. The mice were at a stage similar to a human with Parkinson's who has lost 70% of his/her ability to produce dopamine. After administering CDNF to these rats, they found that 58% of the dopamine-producing cells were alive, compared to 26% in a control group.
Dr Mart Saarma, team leader, University of Helsinki, said "Our new protein has great potential to be developed as drug for Parkinson's disease, but we need to do more animal experiments and also toxicology studies before we can start clinical trials."
"Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo"
Päivi Lindholm1, Merja H. Voutilainen, Juha Laurén, Johan Peränen, Veli-Matti Leppänen, Jaan-Olle Andressoo, Maria Lindahl, Sanna Janhunen, Nisse Kalkkinen, Tõnis Timmusk, Raimo K. Tuominen & Mart Saarma
Nature 448, 73-77 (5 July 2007) | doi:10.1038/nature05957
Click here to view abstract/letter online
Written by: Christian Nordqvist
Editor: Medical News Today
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today
MLA
14 Feb. 2012. <http://www.medicalnewstoday.com/articles/76843.php>
APA
http://www.medicalnewstoday.com/articles/76843.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Visitor Opinions In Chronological Order (1)
Useful?
posted by E.S.Q. on 17 Jul 2007 at 9:16 pmWhile it is encourage for PD patients to learn of new avenues in research such as this one, it is also frustrating not to be able to get a hold of the substance for one's own trial use. Even to know what foods contain a concentration of the CDNF protein would be helpful; even better would be to find a source for the protein in total , so to speak. Does anyone have that information? Thank you.
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.





